- Report
- December 2024
- 125 Pages
Global
From €4438EUR$4,650USD£3,718GBP
- Report
- October 2024
- 196 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- October 2024
- 183 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- March 2025
- 200 Pages
Global
From €2376EUR$2,490USD£1,991GBP
- Report
- March 2025
- 93 Pages
Global
From €5345EUR$5,600USD£4,478GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2025
- 150 Pages
Global
From €2862EUR$2,999USD£2,398GBP
- Report
- May 2024
- 128 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 131 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 138 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 134 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 129 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Clinical Trials
- November 2024
- 240 Pages
Global
From €2863EUR$3,000USD£2,399GBP
- Report
- October 2024
- 212 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- September 2024
- 314 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Clinical Trials
- June 2024
- 240 Pages
Global
From €2863EUR$3,000USD£2,399GBP
- Report
- April 2024
- 180 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- June 2024
- 174 Pages
Asia Pacific
From €1432EUR$1,500USD£1,199GBP
- Report
- December 2022
- 196 Pages
Global
From €4879EUR$5,292USD£3,950GBP

Rivastigmine is a drug used to treat symptoms of Alzheimer's disease and other forms of dementia. It is a cholinesterase inhibitor, meaning it works by increasing the amount of a chemical messenger in the brain that helps nerve cells communicate with each other. It is used to treat mild to moderate dementia caused by Alzheimer's disease or Parkinson's disease. It is also used to treat mild to moderate dementia caused by Lewy body dementia. Rivastigmine is available in both capsule and patch form.
Rivastigmine is part of the Central Nervous System (CNS) drugs market, which includes drugs used to treat neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy. CNS drugs are used to treat a wide range of conditions, from mild to severe. The CNS drugs market is highly competitive, with many companies offering similar products.
Some companies in the Rivastigmine market include Novartis, Pfizer, Mylan, and Teva Pharmaceuticals. Show Less Read more